SG Improves OS in HR+/HER2− Breast Cancer

Abstract

The antibody–drug conjugate sacituzumab govitecan, or SG, may be a viable option for patients with metastatic HR-positive/HER2-negative breast cancer who have developed resistance to endocrine drugs. In the phase III TROPiCS-02 trial, compared with standard chemotherapy, SG extended both progression-free and overall survival, besides improving quality of life.